Atlas Trials

Sasanlimab As Maintenance Treatment Based on Clinical Response to Neoadjuvant Treatment in Molecularly Categorized Muscle Invasive Bladder Cancer Patients

Clinical trial NCT06623162 · NOT_YET_RECRUITING

Trial details

NCT number
NCT06623162
Sponsor
Fundación de investigación HM
Status
NOT_YET_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
MibcMuscle Invasive Bladder Cancer
Start date
2024-12-01
Primary completion
2026-12-01
Enrollment
70

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.